IL6 and cancer: We reasoned that increased circulating IL-6 during cancer progression readily enters the AP and results in AP neuron activation – like the intravenously administered exogenous IL-6 (Fig. 1) – leading to hyperactivity in these neurons, which results in AP network hyperactivity and ultimately cachexia.